BCL2 and breast carcinoma: β-SDG inhibits the proliferation of breast cancer cells by elevating the levels of pro-apoptotic Bax and BCL2 associated agonist of cell death (Bad), and reducing the levels of anti-apoptotic Bcl-2 and Bcl-xl.